ME Jan 2025 1.000 call
| Previous close | 0.0400 |
| Open | 0.0400 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 1.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0400 - 0.0400 |
| Contract range | N/A |
| Volume | |
| Open interest | 12.88k |
Reuters23andMe settles data breach lawsuit for $30 million
(Reuters) - 23andMe will pay $30 million and provide three years of security monitoring to settle a lawsuit accusing the genetics testing company of failing to protect the privacy of 6.9 million customers whose personal information was exposed in a data breach last year. The accord also resolves accusations that 23andMe did not tell customers with Chinese and Ashkenazi Jewish ancestry that the hacker appeared to have specifically targeted them, and posted their information for sale on the dark web. It includes cash payments for customers whose data was compromised, and lets customers enroll for three years in a program known as Privacy & Medical Shield + Genetic Monitoring.
GlobeNewswireOne of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse populationSUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at National Human Genome Research Institute, part of the National Institutes of Health (NIH), and Johns Hopkins University, conducted one of
Reuters23andMe CEO Wojcicki open to third-party takeover proposals for firm, filing shows
The genetic testing firm's shares were up 2.8% at $0.31 in extended trade. In July, Wojcicki, who has been trying to take the company private, proposed to acquire all outstanding shares of 23andMe not owned by her or her affiliates for $0.40 per share. The filing also said the CEO continues to evaluate and negotiate a deal.
